{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:29:03Z","timestamp":1791613743221,"version":"4.3.4"},"reference-count":238,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.immuni.2021.01.015","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T19:31:22Z","timestamp":1615318282000},"page":"412-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-2639","authenticated-orcid":false,"given":"John","family":"Misasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.immuni.2021.01.015_bib1","doi-asserted-by":"crossref","first-page":"S957","DOI":"10.1093\/infdis\/jir326","article-title":"Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis","volume":"204","author":"Aleksandrowicz","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib2","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1128\/JVI.00649-15","article-title":"Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques","volume":"89","author":"Alfson","year":"2015","journal-title":"J.\u00a0Virol."},{"issue":"Suppl 2","key":"10.1016\/j.immuni.2021.01.015_bib3","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1093\/infdis\/jiv216","article-title":"Genetic changes at the glycoprotein editing site associated with serial passage of Sudan virus","volume":"212","author":"Alfson","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v10110642","article-title":"Intramuscular exposure of macaca fascicularis to low doses of low passage-or cell culture-adapted Sudan virus or ebola virus","volume":"10","author":"Alfson","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.immuni.2021.01.015_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/vim.2017.0129","article-title":"Antibody immunodominance: the key to understanding influenza virus antigenic drift","volume":"31","author":"Altman","year":"2018","journal-title":"Viral Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib6","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1128\/JVI.76.13.6841-6844.2002","article-title":"C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans","volume":"76","author":"Alvarez","year":"2002","journal-title":"J.\u00a0Virol."},{"issue":"Suppl 1","key":"10.1016\/j.immuni.2021.01.015_bib7","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s10875-010-9405-6","article-title":"A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs","volume":"30","author":"Anthony","year":"2010","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/7422","article-title":"Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients","volume":"5","author":"Baize","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2249.2002.01800.x","article-title":"Inflammatory responses in Ebola virus-infected patients","volume":"128","author":"Baize","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib10","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1016\/j.jmb.2016.05.008","article-title":"Rodent-adapted filoviruses and the molecular basis of pathogenesis","volume":"428","author":"Banadyga","year":"2016","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.immuni.2021.01.015_bib11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1074-7613(02)00287-X","article-title":"FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses","volume":"16","author":"Barnes","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2021.01.015_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(18)31387-4","article-title":"Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April-May, 2018: an epidemiological study","volume":"392","author":"Barry","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2021.01.015_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00281-017-0637-x","article-title":"Molecular pathogenesis of viral hemorrhagic fever","volume":"39","author":"Basler","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.immuni.2021.01.015_bib14","doi-asserted-by":"crossref","first-page":"12289","DOI":"10.1073\/pnas.220398297","article-title":"The Ebola virus VP35 protein functions as a type I IFN antagonist","volume":"97","author":"Basler","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib15","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1128\/JVI.77.14.7945-7956.2003","article-title":"The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3","volume":"77","author":"Basler","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib16","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/s41467-017-01708-9","article-title":"Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein","volume":"8","author":"Battles","year":"2017","journal-title":"Nat. Commun."},{"issue":"Suppl 2","key":"10.1016\/j.immuni.2021.01.015_bib17","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1086\/520545","article-title":"Assessment of the risk of Ebola virus transmission from bodily fluids and fomites","volume":"196","author":"Bausch","year":"2007","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib18","doi-asserted-by":"crossref","first-page":"e29608","DOI":"10.1371\/journal.pone.0029608","article-title":"The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy","volume":"7","author":"Beniac","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.immuni.2021.01.015_bib19","first-page":"489","article-title":"Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology","volume":"28","author":"Berry","year":"2011","journal-title":"N.\u00a0Biotechnol."},{"key":"10.1016\/j.immuni.2021.01.015_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2141.2005.05884.x","article-title":"Direct targeting of genetically modified tumour cells to Fc c RI triggers potent tumour cytotoxicity.","volume":"132","author":"Bevaart","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.immuni.2021.01.015_bib21","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.1120453109","article-title":"Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography","volume":"109","author":"Bharat","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib22","first-page":"270","article-title":"[Development and study of the properties of immunoglobulin against Ebola fever]","volume":"40","author":"Borisevich","year":"1995","journal-title":"Vopr. Virusol."},{"key":"10.1016\/j.immuni.2021.01.015_bib23","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A two-antibody pan-Ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2021.01.015_bib25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in\u00a0vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1172\/JCI72676","article-title":"Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity","volume":"124","author":"Bournazos","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2021.01.015_bib27","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1084\/jem.20151267","article-title":"The role of Fc-Fc\u03b3R interactions in IgG-mediated microbial neutralization","volume":"212","author":"Bournazos","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib28","doi-asserted-by":"crossref","first-page":"20054","DOI":"10.1073\/pnas.1911842116","article-title":"Differential requirements for Fc\u03b3R engagement by protective antibodies against Ebola virus","volume":"116","author":"Bournazos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41467-018-08040-w","article-title":"Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates","volume":"10","author":"Brannan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2021.01.015_bib30","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1099\/0022-1317-82-6-1365","article-title":"The role of the Type I interferon response in the resistance of mice to filovirus infection","volume":"82","author":"Bray","year":"2001","journal-title":"J.\u00a0Gen. Virol."},{"issue":"Suppl 1","key":"10.1016\/j.immuni.2021.01.015_bib31","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1086\/514292","article-title":"A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever","volume":"179","author":"Bray","year":"1999","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/jcpa.2001.0503","article-title":"Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus","volume":"125","author":"Bray","year":"2001","journal-title":"J.\u00a0Comp. Pathol."},{"key":"10.1016\/j.immuni.2021.01.015_bib33","first-page":"245","article-title":"[The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: introductory note]","volume":"56","author":"Br\u00e8s","year":"1978","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.immuni.2021.01.015_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.virol.2011.04.002","article-title":"Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein","volume":"415","author":"Brindley","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib35","first-page":"271","article-title":"Ebola haemorrhagic fever in Zaire, 1976. Report of an international commission","volume":"56","author":"Burke","year":"1978","journal-title":"Bull. World Health Organ."},{"issue":"suppl_5","key":"10.1016\/j.immuni.2021.01.015_bib36","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1093\/infdis\/jiy450","article-title":"Vaccine-mediated induction of an Ebolavirus cross-species antibody binding to conserved epitopes on the glycoprotein heptad repeat 2\/membrane-proximal external junction","volume":"218","author":"Cagigi","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib37","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann-Pick C1","volume":"477","author":"Carette","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2021.01.015_bib38","series-title":"Outbreaks\u2014Ebola (Ebola Virus Disease)","year":"2020"},{"key":"10.1016\/j.immuni.2021.01.015_bib39","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1110656","article-title":"Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection","volume":"308","author":"Chandran","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib40","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.1073\/pnas.1610803113","article-title":"Glycoengineering of plants yields glycoproteins with polysialylation and other defined N-glycoforms","volume":"113","author":"Chen","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib41","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMp1413084","article-title":"Ebola virus disease in West Africa--clinical manifestations and management","volume":"371","author":"Chertow","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cytogfr.2014.06.005","article-title":"Regulation of RIG-I-like receptor signaling by host and viral proteins","volume":"25","author":"Chiang","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.immuni.2021.01.015_bib43","series-title":"The Arenaviridae","first-page":"331","article-title":"Ecology and epidemiology of arenaviruses","author":"Childs","year":"1993"},{"key":"10.1016\/j.immuni.2021.01.015_bib44","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1128\/JVI.00659-11","article-title":"Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection","volume":"85","author":"Cilloniz","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib45","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection","volume":"477","author":"C\u00f4t\u00e9","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2021.01.015_bib47","series-title":"Notes for the Record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD)","author":"Cox","year":"2018"},{"key":"10.1016\/j.immuni.2021.01.015_bib48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3201\/eid2202.151250","article-title":"Prognostic indicators for Ebola patient survival","volume":"22","author":"Crowe","year":"2016","journal-title":"Emerg. Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.immuni.2021.01.015_bib49","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1093\/infdis\/jiv140","article-title":"Analysis of Ebola virus entry into macrophages","volume":"212","author":"Dahlmann","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib50","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2021.01.015_bib51","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"Davey","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib52","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1128\/JVI.01490-15","article-title":"Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies","volume":"89","author":"Davidson","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib53","first-page":"247","article-title":"Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO\/International Study Team","volume":"56","author":"Deng","year":"1978","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.immuni.2021.01.015_bib238","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2016.10.014","article-title":"Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013\u20132016 Epidemic","volume":"167","author":"Diehl","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in\u00a0vivo","volume":"20","author":"Dilillo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/MMBR.05023-11","article-title":"Viral quasispecies evolution","volume":"76","author":"Domingo","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.immuni.2021.01.015_bib56","series-title":"Filovirus Animal Non-Clinical Group (FANG) Workshop","article-title":"Strain selection and seed stocks","author":"Donaldson","year":"2019"},{"key":"10.1016\/j.immuni.2021.01.015_bib57","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1128\/JVI.01956-08","article-title":"The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding","volume":"83","author":"Dube","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib58","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.1200409109","article-title":"Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease","volume":"109","author":"Dye","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib59","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.ppat.0020073","article-title":"Molecular determinants of Ebola virus virulence in mice","volume":"2","author":"Ebihara","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib61","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jcp.31.3.201","article-title":"Ultrastructure of Ebola virus particles in human liver","volume":"31","author":"Ellis","year":"1978","journal-title":"J.\u00a0Clin. Pathol."},{"key":"10.1016\/j.immuni.2021.01.015_bib62","first-page":"584","article-title":"Ebola virus: a comparison, at ultrastructural level, of the behaviour of the Sudan and Zaire strains in monkeys","volume":"59","author":"Ellis","year":"1978","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.immuni.2021.01.015_bib63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/bmj.2.6086.541","article-title":"A case of Ebola virus infection","volume":"2","author":"Emond","year":"1977","journal-title":"BMJ"},{"key":"10.1016\/j.immuni.2021.01.015_bib64","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1128\/JVI.01160-10","article-title":"Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway","volume":"85","author":"Fabozzi","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib65","series-title":"FDA Approves First Treatment for Ebola Virus","year":"2020"},{"key":"10.1016\/j.immuni.2021.01.015_bib66","series-title":"FDA Approves Treatment for Ebola Virus","year":"2020"},{"key":"10.1016\/j.immuni.2021.01.015_bib67","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1074\/jbc.M510171200","article-title":"The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms","volume":"281","author":"Ferrara","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2021.01.015_bib68","doi-asserted-by":"crossref","first-page":"E2385","DOI":"10.1073\/pnas.1505292112","article-title":"Protection in antibody- and T\u00a0cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs","volume":"112","author":"Fiebiger","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib69","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nm1288","article-title":"Loss of function of a lupus- associated Fc g RIIb polymorphism through exclusion from lipid rafts","volume":"11","author":"Floto","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib70","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebolavirus article cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib71","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41564-018-0157-z","article-title":"Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2\u2013MPER region","volume":"3","author":"Flyak","year":"2018","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.immuni.2021.01.015_bib72","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","article-title":"Mechanism of human antibody-mediated neutralization of Marburg virus","volume":"160","author":"Flyak","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib73","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1084\/jem.191.8.1293","article-title":"Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in\u00a0vivo with the low-affinity Fc receptor III","volume":"191","author":"Fossati-jimack","year":"2000","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib74","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2021.01.015_bib75","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0002-9440(10)63591-2","article-title":"Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection","volume":"163","author":"Geisbert","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.immuni.2021.01.015_bib76","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0002-9440(10)63592-4","article-title":"Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells","volume":"163","author":"Geisbert","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.immuni.2021.01.015_bib77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/jcpa.2001.0502","article-title":"Pathogenesis of experimental Ebola Zaire virus infection in BALB\/c mice","volume":"125","author":"Gibb","year":"2001","journal-title":"J.\u00a0Comp. Pathol."},{"key":"10.1016\/j.immuni.2021.01.015_bib78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2005.06.026","article-title":"LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus","volume":"340","author":"Gramberg","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.virol.2007.11.001","article-title":"Interactions of LSECtin and DC-SIGN\/DC-SIGNR with viral ligands: Differential pH dependence, internalization and virion binding","volume":"373","author":"Gramberg","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib80","doi-asserted-by":"crossref","first-page":"e1002847","DOI":"10.1371\/journal.ppat.1002847","article-title":"The Ebola virus glycoprotein contributes to but is not sufficient for virulence in\u00a0vivo","volume":"8","author":"Groseth","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib81","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus","volume":"24","author":"Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2021.01.015_bib82","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1371\/journal.ppat.0030086","article-title":"The Ebola virus VP35 protein is a suppressor of RNA silencing","volume":"3","author":"Haasnoot","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib83","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1084\/jem.20052283","article-title":"Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy","volume":"203","author":"Hamaguchi","year":"2006","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib84","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","article-title":"Viral membrane fusion","volume":"479-480","author":"Harrison","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib85","doi-asserted-by":"crossref","first-page":"41830","DOI":"10.1074\/jbc.M307036200","article-title":"Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide","volume":"278","author":"Hartlieb","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2021.01.015_bib86","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1073\/pnas.0606730104","article-title":"Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association","volume":"104","author":"Hartlieb","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib87","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1128\/JVI.02344-07","article-title":"Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus","volume":"82","author":"Hartman","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib88","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","article-title":"Structural basis for Marburg virus neutralization by a cross-reactive human antibody","volume":"160","author":"Hashiguchi","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaz2686","article-title":"Multiple roles for HIV broadly neutralizing antibodies","volume":"11","author":"Haynes","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib90","doi-asserted-by":"crossref","first-page":"e1000904","DOI":"10.1371\/journal.ppat.1000904","article-title":"Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species","volume":"6","author":"Hensley","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib91","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"issue":"Suppl 2","key":"10.1016\/j.immuni.2021.01.015_bib92","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1093\/infdis\/jiv111","article-title":"Soluble glycoprotein is not required for Ebola virus virulence in guinea pigs","volume":"212","author":"Hoenen","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib93","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.3390\/v4123336","article-title":"Host cell factors in filovirus entry: novel players, new insights","volume":"4","author":"Hofmann-Winkler","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.immuni.2021.01.015_bib94","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1128\/JVI.01388-13","article-title":"Antibody recognition of the pandemic H1N1 influenza virus hemagglutinin receptor binding site","volume":"87","author":"Hong","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib95","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JVI.02151-09","article-title":"Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity","volume":"84","author":"Hood","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib96","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","article-title":"Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site","volume":"15","author":"Howell","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2021.01.015_bib97","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/JVI.01278-09","article-title":"The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus","volume":"85","author":"Hunt","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib98","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S1473-3099(15)00144-9","article-title":"Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study","volume":"15","author":"Hunt","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib99","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1074-7613(02)00294-7","article-title":"FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection","volume":"16","author":"Ioan-Facsinay","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2021.01.015_bib100","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1128\/JVI.00557-16","article-title":"Biphasic CD8+ T-cell defense in simian immunodeficiency virus control by acute-phase passive neutralizing antibody immunization","volume":"90","author":"Iseda","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib101","first-page":"135","article-title":"Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch. Virol. Suppl."},{"key":"10.1016\/j.immuni.2021.01.015_bib102","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1038\/s41467-018-06113-4","article-title":"Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop","volume":"9","author":"Janus","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2021.01.015_bib103","doi-asserted-by":"crossref","first-page":"15748","DOI":"10.1073\/pnas.0403812101","article-title":"CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus","volume":"101","author":"Jeffers","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib104","doi-asserted-by":"crossref","first-page":"12463","DOI":"10.1128\/JVI.76.24.12463-12472.2002","article-title":"Covalent modifications of the ebola virus glycoprotein","volume":"76","author":"Jeffers","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib105","doi-asserted-by":"crossref","first-page":"e1003232","DOI":"10.1371\/journal.ppat.1003232","article-title":"TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine","volume":"9","author":"Jemielity","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib106","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/infdis\/164.4.646","article-title":"Two-drug combinations of zidovudine, didanosine, and recombinant interferon-\u03b1 A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in\u00a0vitro","volume":"164","author":"Johnson","year":"1991","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib107","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/imr.12005","article-title":"Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA","volume":"250","author":"Julien","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.immuni.2021.01.015_bib108","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/glycob\/cwl057","article-title":"Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types","volume":"17","author":"Kanda","year":"2007","journal-title":"Glycobiology"},{"key":"10.1016\/j.immuni.2021.01.015_bib109","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/JVI.02172-15","article-title":"Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein","volume":"90","author":"Keck","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib110","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"13","author":"Keller","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.immuni.2021.01.015_bib111","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4049\/jimmunol.164.2.953","article-title":"Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils","volume":"164","author":"Kindzelskii","year":"2000","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib112","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41467-019-09732-7","article-title":"Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk","volume":"10","author":"King","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2021.01.015_bib113","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.1073\/pnas.1019030108","article-title":"T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus","volume":"108","author":"Kondratowicz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Suppl 1","key":"10.1016\/j.immuni.2021.01.015_bib114","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1086\/514294","article-title":"Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections","volume":"179","author":"Kudoyarova-Zubavichene","year":"1999","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib115","doi-asserted-by":"crossref","first-page":"e50316","DOI":"10.1371\/journal.pone.0050316","article-title":"Ebola virus genome plasticity as a marker of its passaging history: a comparison of in\u00a0vitro passaging to non-human primate infection","volume":"7","author":"Kugelman","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.immuni.2021.01.015_bib116","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1172\/JCI83111","article-title":"Blood kinetics of Ebola virus in survivors and nonsurvivors","volume":"125","author":"Lanini","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2021.01.015_bib117","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib118","doi-asserted-by":"crossref","first-page":"E7987","DOI":"10.1073\/pnas.1708052114","article-title":"Structure of the Ebola virus envelope protein MPER\/TM domain and its interaction with the fusion loop explains their fusion activity","volume":"114","author":"Lee","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib119","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2021.01.015_bib120","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(00)02405-3","article-title":"Human asymptomatic Ebola infection and strong inflammatory response","volume":"355","author":"Leroy","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2021.01.015_bib121","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2249.2001.01517.x","article-title":"Early immune responses accompanying human asymptomatic Ebola infections","volume":"124","author":"Leroy","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib122","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.4049\/jimmunol.1200501","article-title":"Impact of immune complex size and glycosylation on IgG binding to human Fc\u03b3 Rs","volume":"190","author":"Lux","year":"2019","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib123","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.4049\/jimmunol.170.6.2797","article-title":"Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses","volume":"170","author":"Mahanty","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib124","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0042-6822(03)00233-2","article-title":"Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection","volume":"312","author":"Mahanty","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib125","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1016\/j.immuni.2021.01.015_bib126","doi-asserted-by":"crossref","first-page":"S825","DOI":"10.1093\/infdis\/jir295","article-title":"Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles","volume":"204","author":"Martinez","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib127","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib128","doi-asserted-by":"crossref","first-page":"e36192","DOI":"10.1371\/journal.pone.0036192","article-title":"Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever","volume":"7","author":"Marzi","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.immuni.2021.01.015_bib129","doi-asserted-by":"crossref","first-page":"e1005859","DOI":"10.1371\/journal.ppat.1005859","article-title":"Engineering, structure and immunogenicity of the human metapneumovirus F protein in the postfusion conformation","volume":"12","author":"M\u00e1s","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib130","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3390\/molecules20022229","article-title":"Human lectins and their roles in viral infections","volume":"20","author":"Mason","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.immuni.2021.01.015_bib131","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1509773","article-title":"Molecular evidence of sexual transmission of Ebola virus","volume":"373","author":"Mate","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 3","key":"10.1016\/j.immuni.2021.01.015_bib132","doi-asserted-by":"crossref","first-page":"S1011","DOI":"10.1093\/infdis\/jir338","article-title":"VP24 is a molecular determinant of Ebola virus virulence in guinea pigs","volume":"204","author":"Mateo","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib133","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib134","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2015.03.002","article-title":"Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein","volume":"11","author":"McLellan","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib135","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrmicro3524","article-title":"Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus","volume":"13","author":"Messaoudi","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.immuni.2021.01.015_bib136","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/emboj.2012.53","article-title":"Ebola virus entry requires the host-programmed recognition of an intracellular receptor","volume":"31","author":"Miller","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.immuni.2021.01.015_bib137","doi-asserted-by":"crossref","first-page":"eaai8711","DOI":"10.1126\/scitranslmed.aai8711","article-title":"Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody","volume":"9","author":"Mire","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib138","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2014.10.006","article-title":"Camouflage and misdirection: the full-on assault of ebola virus disease","volume":"159","author":"Misasi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib139","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/JVI.06346-11","article-title":"Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences","volume":"86","author":"Misasi","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib140","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib141","doi-asserted-by":"crossref","first-page":"e1003065","DOI":"10.1371\/journal.ppat.1003065","article-title":"Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus","volume":"8","author":"Mohan","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib142","doi-asserted-by":"crossref","first-page":"10572","DOI":"10.1128\/JVI.05541-11","article-title":"A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fc\u03b3 receptors to define the role of effector functions in protection against HIV","volume":"85","author":"Moldt","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib143","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1128\/JVI.00491-12","article-title":"A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fc\u03b3RIIIa-mediated antiviral activity in\u00a0vitro but does not improve protection against mucosal SHIV challenge in macaques","volume":"86","author":"Moldt","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib144","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1128\/JVI.01025-13","article-title":"Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry","volume":"87","author":"Moller-Tank","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib145","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1128\/JVI.00300-14","article-title":"Characterizing functional domains for TIM-mediated enveloped virus entry","volume":"88","author":"Moller-Tank","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib146","doi-asserted-by":"crossref","first-page":"16271","DOI":"10.1038\/nmicrobiol.2016.271","article-title":"A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein","volume":"2","author":"Mousa","year":"2017","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.immuni.2021.01.015_bib147","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/JVI.73.3.2333-2342.1999","article-title":"Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems","volume":"73","author":"M\u00fchlberger","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib148","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib149","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.virol.2011.08.009","article-title":"The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway","volume":"419","author":"Mulherkar","year":"2011","journal-title":"Virology"},{"issue":"Suppl 1","key":"10.1016\/j.immuni.2021.01.015_bib150","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients","volume":"179","author":"Mupapa","year":"1999","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib151","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s13337-020-00619-6","article-title":"Piperine, an alkaloid of black pepper seeds can effectively inhibit the antiviral enzymes of Dengue and Ebola viruses, an in\u00a0silico molecular docking study","volume":"31","author":"Nag","year":"2020","journal-title":"Virusdisease"},{"key":"10.1016\/j.immuni.2021.01.015_bib152","doi-asserted-by":"crossref","first-page":"e1001121","DOI":"10.1371\/journal.ppat.1001121","article-title":"Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner","volume":"6","author":"Nanbo","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib153","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1126\/science.1118948","article-title":"Divergent immunoglobulin G subclass activity through selective Fc receptor binding","volume":"310","author":"Nimmerjahn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib154","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2017.07.010","article-title":"Of mice, macaques, and men: broadly neutralizing antibody immunotherapy for HIV-1","volume":"22","author":"Nishimura","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2021.01.015_bib156","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jmb.2004.01.007","article-title":"Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa","volume":"336","author":"Okazaki","year":"2004","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.immuni.2021.01.015_bib157","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.1213709109","article-title":"Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques","volume":"109","author":"Olinger","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib158","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.ppat.0030009","article-title":"Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys","volume":"3","author":"Oswald","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib159","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1038\/nmicrobiol.2016.128","article-title":"Structures of Ebola virus GP and sGP in complex with therapeutic antibodies","volume":"1","author":"Pallesen","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.immuni.2021.01.015_bib160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/298220d0","article-title":"Be fair to parasites","volume":"298","author":"Palmieri","year":"1982","journal-title":"Nature"},{"issue":"suppl_5","key":"10.1016\/j.immuni.2021.01.015_bib161","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates","volume":"218","author":"Pascal","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib162","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ni.2939","article-title":"Type I and type II Fc receptors regulate innate and adaptive immunity","volume":"15","author":"Pincetic","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib163","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4049\/jimmunol.1700827","article-title":"Ebola immunity: gaining a winning position in lightning chess","volume":"201","author":"Ploquin","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib164","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1128\/JVI.00925-10","article-title":"Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function","volume":"84","author":"Prins","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib165","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clim.2011.08.008","article-title":"Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies","volume":"141","author":"Qiu","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib166","doi-asserted-by":"crossref","first-page":"138ra81","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib167","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2021.01.015_bib168","doi-asserted-by":"crossref","first-page":"329ra33","DOI":"10.1126\/scitranslmed.aad9875","article-title":"Two-mAb cocktail protects macaques against the Makona variant of Ebola virus","volume":"8","author":"Qiu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib169","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/dkt326","article-title":"Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIV","volume":"69","author":"Quan","year":"2014","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.immuni.2021.01.015_bib170","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1128\/JVI.00422-09","article-title":"Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors","volume":"83","author":"Quinn","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib171","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1084\/jem.189.2.371","article-title":"Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization","volume":"189","author":"Regnault","year":"1999","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib172","doi-asserted-by":"crossref","first-page":"13469","DOI":"10.1128\/JVI.01097-07","article-title":"Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1","volume":"81","author":"Reid","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib173","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","article-title":"Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells","volume":"7","author":"Richards","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.immuni.2021.01.015_bib174","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature17949","article-title":"Unique human immune signature of Ebola virus disease in Guinea","volume":"533","author":"Ruibal","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2021.01.015_bib175","doi-asserted-by":"crossref","first-page":"e1000141","DOI":"10.1371\/journal.ppat.1000141","article-title":"Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus","volume":"4","author":"Saeed","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib176","doi-asserted-by":"crossref","first-page":"e1001110","DOI":"10.1371\/journal.ppat.1001110","article-title":"Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes","volume":"6","author":"Saeed","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2021.01.015_bib177","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1126\/science.1258758","article-title":"Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment","volume":"347","author":"Sakurai","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib178","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0042-6822(87)90283-2","article-title":"Identification and analysis of Ebola virus messenger RNA","volume":"157","author":"Sanchez","year":"1987","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib179","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0168-1702(93)90063-S","article-title":"Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus","volume":"29","author":"Sanchez","year":"1993","journal-title":"Virus Res."},{"key":"10.1016\/j.immuni.2021.01.015_bib180","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1073\/pnas.93.8.3602","article-title":"The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing","volume":"93","author":"Sanchez","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib181","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1128\/JVI.72.8.6442-6447.1998","article-title":"Biochemical analysis of the secreted and virion glycoproteins of Ebola virus","volume":"72","author":"Sanchez","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib182","doi-asserted-by":"crossref","first-page":"10370","DOI":"10.1128\/JVI.78.19.10370-10377.2004","article-title":"Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels","volume":"78","author":"Sanchez","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib183","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib184","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib185","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/JVI.80.8.4174-4178.2006","article-title":"Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein","volume":"80","author":"Schornberg","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib186","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1073\/pnas.0807578106","article-title":"Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins","volume":"106","author":"Schornberg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.01.015_bib187","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1158\/0008-5472.CAN-04-4212","article-title":"Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering","volume":"65","author":"Schuster","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2021.01.015_bib188","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib189","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/infdis\/169.4.722","article-title":"Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations","volume":"169","author":"Shafer","year":"1994","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.virol.2010.02.029","article-title":"Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms","volume":"401","author":"Shedlock","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib191","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc \u03b3 RI, Fc \u03b3 RII, Fc \u03b3 RIII, and FcRn and design of IgG1 variants with improved binding to the Fc \u03b3 R","volume":"276","author":"Shields","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2021.01.015_bib192","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2021.01.015_bib193","doi-asserted-by":"crossref","first-page":"10109","DOI":"10.1128\/JVI.01157-06","article-title":"Tyro3 family-mediated cell entry of Ebola and Marburg viruses","volume":"80","author":"Shimojima","year":"2006","journal-title":"J.\u00a0Virol."},{"issue":"Suppl 2","key":"10.1016\/j.immuni.2021.01.015_bib194","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1086\/520594","article-title":"The mechanism of Axl-mediated Ebola virus infection","volume":"196","author":"Shimojima","year":"2007","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/viro.2002.1730","article-title":"DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells","volume":"305","author":"Simmons","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib196","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1473-3099(18)30397-9","article-title":"Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study","volume":"18","author":"Sivapalasingam","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib197","doi-asserted-by":"crossref","first-page":"11247","DOI":"10.1128\/JVI.01657-16","article-title":"Deep sequencing of influenza A virus from a human challenge study reveals a selective bottleneck and only limited intrahost genetic diversification","volume":"90","author":"Sobel Leonard","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib198","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coi.2016.03.005","article-title":"Harnessing Fc receptor biology in the design of therapeutic antibodies","volume":"40","author":"Sondermann","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib199","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.1716788","article-title":"Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase","volume":"253","author":"St Clair","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib200","first-page":"300","article-title":"Membrane binding and bending in Ebola VP40 assembly and egress","volume":"5","author":"Stahelin","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.immuni.2021.01.015_bib201","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"issue":"1, Suppl","key":"10.1016\/j.immuni.2021.01.015_bib202","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: Replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.immuni.2021.01.015_bib203","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1073\/pnas.94.26.14764","article-title":"A system for functional analysis of Ebola virus glycoprotein","volume":"94","author":"Takada","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.immuni.2021.01.015_bib204","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/viro.2000.0601","article-title":"Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry","volume":"278","author":"Takada","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib205","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.3390\/v7122969","article-title":"Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein poly-U editing site populations in the exposure material","volume":"7","author":"Trefry","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.immuni.2021.01.015_bib206","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.immuni.2021.01.015_bib239","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cell.2016.10.013","article-title":"Human Adaptation of Ebola Virus during the West African Outbreak","author":"Urbanowicz","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib207","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMc1609116","article-title":"Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies","volume":"375","author":"van Griensven","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib208","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1006\/viro.1995.0052","article-title":"GP mRNA of ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases1","volume":"214","author":"Volchkov","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2021.01.015_bib209","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1126\/science.1057269","article-title":"Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity","volume":"291","author":"Volchkov","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib210","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1006\/viro.1998.9389","article-title":"The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer","volume":"250","author":"Volchkova","year":"1998","journal-title":"Virology"},{"issue":"Suppl 3","key":"10.1016\/j.immuni.2021.01.015_bib211","doi-asserted-by":"crossref","first-page":"S941","DOI":"10.1093\/infdis\/jir321","article-title":"Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs","volume":"204","author":"Volchkova","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.immuni.2021.01.015_bib212","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1093\/infdis\/jiv309","article-title":"RNA editing of the GP Gene of ebola virus is an important pathogenicity factor","volume":"212","author":"Volchkova","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib213","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02004-17","article-title":"Characterization of H5N1 influenza virus quasispecies with adaptive hemagglutinin mutations from single-virus infections of human airway cells","volume":"92","author":"Watanabe","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib214","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3201\/eid1507.090402","article-title":"Immunoglobulin G in Ebola outbreak survivors, Gabon","volume":"15","author":"Wauquier","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib215","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.aag3267","article-title":"A \u201cTrojan horse\u201d bispecific-antibody strategy for broad protection against ebolaviruses","volume":"354","author":"Wec","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib216","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a human survivor define sites of vulnerability for broad protection against Ebolaviruses","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib217","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.chom.2018.12.004","article-title":"Development of a human antibody cocktail that deploys multiple functions to confer pan-Ebolavirus protection","volume":"25","author":"Wec","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2021.01.015_bib218","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/1743-422X-10-331","article-title":"Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry","volume":"10","author":"Wen","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.immuni.2021.01.015_bib219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.01674-18","article-title":"Structural basis of Pan-Ebolavirus neutralization by a human antibody against a conserved, yet cryptic epitope","volume":"9","author":"West","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.immuni.2021.01.015_bib220","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41594-019-0191-4","article-title":"Structural basis of broad ebolavirus neutralization by a human survivor antibody","volume":"26","author":"West","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.immuni.2021.01.015_bib221","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib222","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1126\/science.1546316","article-title":"Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants","volume":"255","author":"Wolinsky","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib223","doi-asserted-by":"crossref","first-page":"158ra146","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"suppl 3","key":"10.1016\/j.immuni.2021.01.015_bib224","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1093\/infdis\/jiw267","article-title":"Pathogenicity comparison between the Kikwit and Makona Ebola virus variants in rhesus macaques","volume":"214","author":"Wong","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.01.015_bib225","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1128\/JVI.72.4.3155-3160.1998","article-title":"Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines","volume":"72","author":"Wool-Lewis","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib237","year":"2020"},{"key":"10.1016\/j.immuni.2021.01.015_bib226","first-page":"1","article-title":"Ebola Virus Disease Democratic Republic of the Congo: External Situation Report","volume":"98","year":"2020"},{"key":"10.1016\/j.immuni.2021.01.015_bib227","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib228","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1128\/JVI.00145-09","article-title":"Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection","volume":"83","author":"Yamamoto","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.01.015_bib229","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1126\/science.279.5353.1034","article-title":"Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins","volume":"279","author":"Yang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib230","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/78654","article-title":"Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury","volume":"6","author":"Yang","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2021.01.015_bib231","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in\u00a0vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.immuni.2021.01.015_bib232","doi-asserted-by":"crossref","first-page":"e9294","DOI":"10.1371\/journal.pone.0009294","article-title":"Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants","volume":"5","author":"Zhang","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.immuni.2021.01.015_bib233","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","article-title":"Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability","volume":"169","author":"Zhao","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.01.015_bib234","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coi.2015.06.006","article-title":"Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine","volume":"35","author":"Zhou","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.immuni.2021.01.015_bib235","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.01.015_bib236","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1128\/JVI.05741-11","article-title":"Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cells","volume":"86","author":"Zhu","year":"2012","journal-title":"J.\u00a0Virol."}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761321000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761321000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:11:59Z","timestamp":1761034319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761321000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":238,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1074761321000388"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2021.01.015","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2021.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}